A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
|Articles|January 14, 2022
Daily OTC Pearl: Midol Complete
Author(s)Saro Arakelians, PharmD
Advertisement
OTC/Lifestyle Pearl of the Day: Midol Complete
Indication: For painful menstruation, typically involving abdominal cramps.
Insight:
- Dosage: 2 caplets every 6 hrs, max 6 per day.
- Ingredients: Acetaminophen 500 mg, caffeine 60 mg, pyrilamine maleate 15 mg; caplets.
- Contraindication: Concomitant other acetaminophen-containing products.
- Warning: Acetaminophen has an increased risk of hepatotoxicity if overdosage or ≥3 alcoholic drinks/day. Pyrilamine potentiates central nervous system (CNS) depression with alcohol and other CNS depressants. Caution with warfarin, sedatives, or tranquilizers.
- Adverse events: Acetaminophen—hepatotoxicity (overdosage). Pyrilamine—drowsiness, dizziness, paradoxical excitation (especially in children). Caffeine—nervousness, irritability, sleeplessness, and occasional palpitations.
- Dosage forms: Caplets, complete, #24.
Sources:
Advertisement
Related to this article
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Advertisement
Advertisement